374 related articles for article (PubMed ID: 26147622)
21. Evaluation of candidate nephropathy susceptibility genes in a genome-wide association study of African American diabetic kidney disease.
Palmer ND; Ng MC; Hicks PJ; Mudgal P; Langefeld CD; Freedman BI; Bowden DW
PLoS One; 2014; 9(2):e88273. PubMed ID: 24551085
[TBL] [Abstract][Full Text] [Related]
22. APOL1 genetic variants, chronic kidney diseases and hypertension in mixed ancestry South Africans.
Matsha TE; Kengne AP; Masconi KL; Yako YY; Erasmus RT
BMC Genet; 2015 Jun; 16():69. PubMed ID: 26112018
[TBL] [Abstract][Full Text] [Related]
23. APOL1 nephropathy risk variants are associated with altered high-density lipoprotein profiles in African Americans.
Gutiérrez OM; Judd SE; Irvin MR; Zhi D; Limdi N; Palmer ND; Rich SS; Sale MM; Freedman BI
Nephrol Dial Transplant; 2016 Apr; 31(4):602-8. PubMed ID: 26152403
[TBL] [Abstract][Full Text] [Related]
24. MYH9 genetic variants associated with glomerular disease: what is the role for genetic testing?
Kopp JB; Winkler CA; Nelson GW
Semin Nephrol; 2010 Jul; 30(4):409-17. PubMed ID: 20807613
[TBL] [Abstract][Full Text] [Related]
25. Keloids and non-diabetic kidney disease: similarities and the APOL1-MYH9 haplotype as a possible genetic link.
Keeling BH; Taylor BR
Med Hypotheses; 2013 Nov; 81(5):908-10. PubMed ID: 24011553
[TBL] [Abstract][Full Text] [Related]
26. Epistatic role of the MYH9/APOL1 region on familial hematuria genes.
Voskarides K; Demosthenous P; Papazachariou L; Arsali M; Athanasiou Y; Zavros M; Stylianou K; Xydakis D; Daphnis E; Gale DP; Maxwell PH; Elia A; Pattaro C; Pierides A; Deltas C
PLoS One; 2013; 8(3):e57925. PubMed ID: 23516419
[TBL] [Abstract][Full Text] [Related]
27. A risk allele for focal segmental glomerulosclerosis in African Americans is located within a region containing APOL1 and MYH9.
Genovese G; Tonna SJ; Knob AU; Appel GB; Katz A; Bernhardy AJ; Needham AW; Lazarus R; Pollak MR
Kidney Int; 2010 Oct; 78(7):698-704. PubMed ID: 20668430
[TBL] [Abstract][Full Text] [Related]
28. Structural characterization of the C-terminal coiled-coil domains of wild-type and kidney disease-associated mutants of apolipoprotein L1.
Sharma AK; Friedman DJ; Pollak MR; Alper SL
FEBS J; 2016 May; 283(10):1846-62. PubMed ID: 26945671
[TBL] [Abstract][Full Text] [Related]
29. Genetic variants and cell-free hemoglobin processing in sickle cell nephropathy.
Saraf SL; Zhang X; Shah B; Kanias T; Gudehithlu KP; Kittles R; Machado RF; Arruda JA; Gladwin MT; Singh AK; Gordeuk VR
Haematologica; 2015 Oct; 100(10):1275-84. PubMed ID: 26206798
[TBL] [Abstract][Full Text] [Related]
30. APOL1-G0 protects podocytes in a mouse model of HIV-associated nephropathy.
Bruggeman LA; Wu Z; Luo L; Madhavan S; Drawz PE; Thomas DB; Barisoni L; O'Toole JF; Sedor JR
PLoS One; 2019; 14(10):e0224408. PubMed ID: 31661509
[TBL] [Abstract][Full Text] [Related]
31. APOL1 Risk Alleles Are Associated with Exaggerated Age-Related Changes in Glomerular Number and Volume in African-American Adults: An Autopsy Study.
Hoy WE; Hughson MD; Kopp JB; Mott SA; Bertram JF; Winkler CA
J Am Soc Nephrol; 2015 Dec; 26(12):3179-89. PubMed ID: 26038529
[TBL] [Abstract][Full Text] [Related]
32. Clinical phenotype of APOL1 nephropathy in young relatives of patients with end-stage renal disease.
Anyaegbu EI; Shaw AS; Hruska KA; Jain S
Pediatr Nephrol; 2015 Jun; 30(6):983-9. PubMed ID: 25530085
[TBL] [Abstract][Full Text] [Related]
33. Protein domains of APOL1 and its risk variants.
Lan X; Wen H; Lederman R; Malhotra A; Mikulak J; Popik W; Skorecki K; Singhal PC
Exp Mol Pathol; 2015 Aug; 99(1):139-44. PubMed ID: 26091559
[TBL] [Abstract][Full Text] [Related]
34. The population genetics of chronic kidney disease: insights from the MYH9-APOL1 locus.
Rosset S; Tzur S; Behar DM; Wasser WG; Skorecki K
Nat Rev Nephrol; 2011 Jun; 7(6):313-26. PubMed ID: 21537348
[TBL] [Abstract][Full Text] [Related]
35. Podocyte-specific deletion of Myh9 encoding nonmuscle myosin heavy chain 2A predisposes mice to glomerulopathy.
Johnstone DB; Zhang J; George B; Léon C; Gachet C; Wong H; Parekh R; Holzman LB
Mol Cell Biol; 2011 May; 31(10):2162-70. PubMed ID: 21402784
[TBL] [Abstract][Full Text] [Related]
36. APOL1 kidney disease risk variants cause cytotoxicity by depleting cellular potassium and inducing stress-activated protein kinases.
Olabisi OA; Zhang JY; VerPlank L; Zahler N; DiBartolo S; Heneghan JF; Schlöndorff JS; Suh JH; Yan P; Alper SL; Friedman DJ; Pollak MR
Proc Natl Acad Sci U S A; 2016 Jan; 113(4):830-7. PubMed ID: 26699492
[TBL] [Abstract][Full Text] [Related]
37. Gene-gene interactions in APOL1-associated nephropathy.
Divers J; Palmer ND; Lu L; Langefeld CD; Rocco MV; Hicks PJ; Murea M; Ma L; Bowden DW; Freedman BI
Nephrol Dial Transplant; 2014 Mar; 29(3):587-94. PubMed ID: 24157943
[TBL] [Abstract][Full Text] [Related]
38. APOL1 and nephropathy progression in populations of African ancestry.
Freedman BI
Semin Nephrol; 2013 Sep; 33(5):425-32. PubMed ID: 24119848
[TBL] [Abstract][Full Text] [Related]
39. The association between APOL1 risk alleles and longitudinal kidney function differs by HIV viral suppression status.
Estrella MM; Li M; Tin A; Abraham AG; Shlipak MG; Penugonda S; Hussain SK; Palella FJ; Wolinsky SM; Martinson JJ; Parekh RS; Kao WH
Clin Infect Dis; 2015 Feb; 60(4):646-52. PubMed ID: 25281610
[TBL] [Abstract][Full Text] [Related]
40. Kidney Disease Progression in Membranous Nephropathy among Black Participants with High-Risk APOL1 Genotype.
Chen DP; Henderson CD; Anguiano J; Aiello CP; Collie MM; Moreno V; Hu Y; Hogan SL; Falk RJ;
Clin J Am Soc Nephrol; 2023 Mar; 18(3):337-343. PubMed ID: 36763808
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
